Andtbacka, R. H., Collichio, F. A., Amatruda, T., Senzer, N., Chesney, J., Delman, K., Spitler, L., Puzanov, I., Agarwala, S., Milhem, M., Harrington, K., Middleton, M., Li, A., Shilkrut, M., Coffin, R., & Kaufman, H. (n.d.). final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704). Journal for immunotherapy of cancer, 2, . http://access.bl.uk/ark:/81055/vdc_100137794000.0x000005